BiologicsSpine

Cerapedics Announces Results from Clinical Trial of i-FACTOR® Peptide Enhanced Bone Graft in Lumbar Fusion Surgery

WESTMINSTER, Colo., May 19, 2020 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today announced that results from a clinical trial evaluating i-FACTOR Peptide Enhanced Bone Graft in non-instrumented lumbar fusion surgery has been published in the May 2020, Volume 20, Issue 5 print of The Spine Journal as the lead article. The data demonstrate that elderly patients in Denmark treated with i-FACTOR bone graft plus local bone had a statistically significantly higher fusion rate compared to allograft plus local bone.

“In Scandinavia, surgeons often consider performing non-instrumented fusion when there is instability in elderly patients, but allograft bone has notoriously low fusion rates in this population,” said Dr. Michael Kjær Jacobsen, principal investigator. “i-FACTOR shows an increased fusion rate versus allograft.”

Dr. Michael Kjær Jacobsen, at the Center for Spine Surgery and Research in Southern Denmark, led the double-blind, prospective, randomized study in more than 100 patients (60 years or older). Participants suffered from degenerative spondylolisthesis and underwent decompression and non-instrumented posterolateral fusion surgery, randomized to either i-FACTOR bone graft or fresh frozen allograft bone, both mixed with local bone graft. Results showed the fusion rate was significantly higher in the i-FACTOR bone graft group (50 percent) compared to the allograft group (20 percent) at one year (p <0.001). Patient reported outcomes at baseline and follow-up were similar between the two groups. Longer term follow-up to evaluate the maintenance of clinical outcomes is in process. 

“This study is a valuable addition to our clinical evidence base,” said Glen Kashuba, chief executive officer of Cerapedics. “This is now our fourth prospective clinical study in which i-FACTOR Bone Graft has demonstrated a clear clinical benefit and builds upon our previously reported fusion in various spine applications.”

“We are very encouraged by the results of this level-1 human clinical study in an extremely challenging environment,” said Jeffrey G. Marx, Ph.D., president, and chief operating officer. “These results are especially encouraging as we continue to advance an investigational device exemption (IDE) clinical trial in the U.S. evaluating the safety and efficacy of our next-generation bone graft in transforaminal lumbar interbody fusion (TLIF) surgery.”

i‑FACTOR bone graft has over 10 years of clinical success in Europe and was approved in the U.S. for use in anterior cervical discectomy and fusion (ACDF) procedures in 2015. The drug-device combination product is based on small peptide (P-15) technology that accelerates new bone formation in patients with degenerative disc disease. It is in a new category of bone graft technology and is one of only two drug-device combination products approved by the U.S. Food & Drug Administration (FDA). In 2018, the company enrolled the first patients in an IDE clinical trial evaluating the safety and efficacy of its next-generation product, P-15L Peptide Enhanced Bone Graft, for use in patients undergoing TLIF fusion surgery.

CAUTION:  In the United States, i-FACTOR Peptide Enhanced Bone Graft is indicated for use in skeletally mature patients for reconstruction of a degenerated cervical disc at one level from C3-C4 to C6-C7 following single-level discectomy for intractable radiculopathy (arm pain and/or a neurological deficit), with or without neck pain, or myelopathy due to a single-level abnormality localized to the disc space, and corresponding to at least one of the following conditions confirmed by radiographic imaging (CT, MRI, X-rays): herniated nucleus pulposus, spondylosis (defined by the presence of osteophytes), and/or visible loss of disc height as compared to adjacent levels, after failure of at least 6 weeks of conservative treatment.  i-FACTOR Peptide Enhanced Bone Graft must be used inside an allograft bone ring and with supplemental anterior plate fixation.

About Cerapedics
Cerapedics is an ortho-biologics company focused on developing and commercializing its proprietary small peptide (P-15) technology platform. i-FACTOR Peptide Enhanced Bone Graft is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. This novel mechanism of action is designed to support safer and more predictable bone formation compared to commercially available bone growth factors. More information can be found here.

Media contact:
Drew Trivisonno
CFO, Cerapedics Inc.
720-712-1730
media@cerapedics.com

SOURCE Cerapedics Inc.

Related Links

http://www.cerapedics.com

Print Friendly, PDF & Email
Tags

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button
Close